scientific reports

A vector system encoding OPEN histone H3 mutants facilitates manipulations of the neuronal epigenome

SophieWarren, Sen Xiong, Daisy Robles-Magallanes & José-Manuel Baizabal

The differentiation of developmental cell lineages is associated with genome-wide modifications in histone H3 methylation. However, the causal role of histone H3 methylation in transcriptional regulation and cell differentiation has been difficult to test in mammals. The experimental overexpression of histone H3 mutants carrying lysine-to-methionine (K-to-M) substitutions has emerged as an alternative tool for inhibiting the endogenous levels of histone H3 methylation at specific lysine residues. Here, we leverage the use of histone K-to-M mutants by creating Enhanced Episomal Vectors that enable the simultaneous depletion of multiple levels of histone H3 lysine 4 (H3K4) or lysine 9 (H3K9) methylation in projection neurons of the mouse cerebral cortex. Our approach also facilitates the simultaneous depletion of H3K9 and H3K27 trimethylation (H3K9me3 and H3K27me3, respectively) in cortical neurons. In addition, we report a tamoxifen-inducible Cre-FLEX system that allows the activation of mutant histones at specific developmental time points or in the adult cortex, leading to the depletion of specific histone marks. The tools presented here can be implemented in other experimental systems, such as human in vitro models, to test the combinatorial role of histone methylations in developmental fate decisions and the maintenance of cell identity.

Cell diversity in the adult organism arises during embryonic development from the activation of cell-typespecific transcriptional programs. Lysine methylation at the amino-terminal region of histone H3 is a chromatin post-translational modification associated with distinct transcriptional states¹. The "histone code" model postulates that the combinatorial or sequential activity of histone methylations at multiple lysine residues determines the transcriptional output —and thereby the identity— of a cell^{[2,](#page-10-1)[3](#page-10-2)}. Notably, genome-wide alterations in histone methylation are associated with human developmental disorders, cancer, and aging^{[1](#page-10-0)}. However, testing the individual and combined roles of histone methylations on developmental fate specification, differentiation, and the maintenance of cell identity, remains a major technical roadblock that demands the generation and optimization of novel experimental tools and approaches^{[4](#page-10-3)}.

The analysis of gene regulation by histone H3 methylation is substantially complicated by the presence of mono-, di-, and trimethylated lysine residues^{[1](#page-10-0)}. In some cases, distinct levels of histone H3 methylation are enriched at different *cis*-regulatory elements in the genome. For instance, histone H3 lysine 4 monomethylation (H3K4me1) preferentially marks active or poised enhancers, whereas lysine 4 trimethylation (H3K4me3) is mostly present at the promoter of actively transcribed genes^{[5](#page-10-4)[,6](#page-10-5)}. Nonetheless, it remains unclear whether H3K4 methylation plays a primary role in gene activation^{[4](#page-10-3)[,7](#page-10-6)}. In other instances, multiple levels of methylation on a lysine residue might have redundant roles in controlling specific transcriptional outputs. In this regard, histone H3 lysine 9 di- and trimethylation (H3K9me2 and H3K9me3, respectively) are both linked to transcriptional repression^{[8](#page-10-7)}. However, the unique and cooperative roles of H3K9me2 and H3K9me3 in gene silencing and their functional crosstalk with other repressive marks, such as histone H3 lysine 27 trimethylation (H3K27me3), remain mostly unknown^{[9](#page-10-8)}.

The main experimental approach to study the role of histone methylation in mammalian cells is the generation of loss-of-function mutations in the genes encoding for histone methyltransferases^{[4](#page-10-3)}. The main caveat of this approach is that histone methylations are usually produced by the redundant activity of several chromatin-modifying enzymes¹⁰. Therefore, attaining full depletion of particular histone methylations in vivo usually requires complex mouse genetic models that consist of multiple mutated genes in specific cell types¹¹. Furthermore, chromatin-modifying enzymes have non-histone methylation substrates or methylation-

Department of Biology, Indiana University, Bloomington, IN 47405, USA. [⊠]email: mbaizaba@iu.edu

independent activities $12-14$ $12-14$, thereby complicating the interpretation of the results using loss-of-function alleles for histone methyltransferases.

Somatic mutations that substitute a lysine (K) with methionine (M) at specific positions in the N-terminal tails of histone H3 were initially discovered in some types of cancer in humans¹⁵. Histone H3 K-to-M mutations function as dominant negative molecules by repressing the activity of the histone methyltransferases targeting a specific lysine residue on the endogenous histone H3, thereby blocking the methylation of that residue (Fig. [1\)](#page-1-0)¹⁶. For example, experimental overexpression of a mutant histone H3 carrying a lysine 27-to-methionine substitution (H3K27M) acts primarily as an inhibitor of the H3K27 methyltransferase EZH2, resulting in the depletion of H3K27me3 in the endogenous histone H3[16.](#page-10-14) Likewise, overexpression of histone H3K9M blocks the activity of H3K9 methyltransferases, such as SUV39H1, leading to H3K9me3 depletion in the endogenous histone H3^{[16](#page-10-14)}. Moreover, integration of the histone K-to-M mutant into nucleosomes is expected to locally reduce H3 methylation, as methionine is not a substrate for methylation (Fig. [1](#page-1-0))[17.](#page-10-15) However, the direct mechanisms (*cis*effects) of histone methylation inhibition by K-to-M mutants are less prominent than the indirect mechanisms (*trans*-effects) on histone methyltransferases (Fig. [1\)](#page-1-0)^{[16](#page-10-14)}.

Several groups have implemented the experimental overexpression of histone H3 K-to-M mutants in multiple systems to deplete the endogenous histone H3 methylation without introducing mutations in the genes encoding for histone H3 methyltransferases¹⁵. This approach has been used in invertebrates to test the role of histone H3K27 methylation in *Caenorhabditis elegans*[18](#page-11-0) and H3K9, H3K27, and H3K36 methylation in *Drosophila melanogaster*[19–](#page-11-1)[21.](#page-11-2) In mammals, histone K-to-M mutants have been used to study the role of H3K9 and H3K36 methylation in mouse embryonic stem cells (mESCs) and adult hematopoietic cells in vivo 22 , as well as the function of H3K27 methylation in pediatric gliomas using human neural progenitors in vitro 23 . These studies indicate that histone H3 K-to-M mutants are effective tools to study chromatin biology in model organisms.

Here, we leveraged the use of histone K-to-M mutants to deplete various histone H3 methylations in developing and mature neurons of the mouse cerebral cortex. We present a series of molecular vectors to achieve three goals in vivo: (1) Robust and simultaneous depletion of two levels of histone H3 methylation at a single lysine residue; (2) Concurrent removal of histone H3 methylation at two independent lysine residues; (3) Temporal control of methylation depletion at specific stages of neuronal differentiation. Our tools can be implemented in other systems to study the regulation of gene expression by multiple levels of histone methylations and their crosstalk in specific cell types of developing and adult mice or in vitro human models of cell differentiation.

Fig. 1. Inhibition of histone H3 methylation. Overexpression of histone H3 K-to-M mutants (yellow circle) results in the inhibition of specific groups of lysine methyltransferases, leading to the indirect depletion of lysine methylation (shown as "K-me") on the endogenous histone H3 (indirect mechanism). The mutant transgene is also incorporated into the nucleosomes, which results in an unmethylated methionine (direct mechanism).

Results

We aimed to deplete specific histone H3 methylations in early postnatal neurons of the mouse cerebral cortex by performing *in utero* electroporation (IUE) of plasmids encoding for histone H3 K-to-M mutants. One caveat of this approach is that plasmids are initially electroporated into proliferating neural stem cells (NSCs) and progenitors at the ventricular zone of the embryonic cortex²⁴, which is expected to result in reduced concentration of the molecular vectors over multiple rounds of cell division and lower gene expression levels upon neuronal differentiation. To decrease plasmid dilution in proliferating cells, we generated a series of Enhanced Episomal Vectors (EEVs) based on Epstein-Barr virus sequences²⁵. The vectors consisted of a constitutively active CAG promoter driving the expression of the WT histone H3.3 A isoform (*H3f3a*[\)26](#page-11-7) or K-to-M mutants on lysine 4 (H3K4M), 9 (H3K9M), and 27 (H3K27M) upstream an internal ribosome entry site (IRES) and nuclear GFP (Supplementary Fig. 1). The EEVs also contained the EBNA1 (Epstein–Barr virus nuclear antigen 1) and oriP (origin of replication) sequences (Supplementary Fig. $1)^{25}$, which are known to maintain high transgene expression in proliferating mouse cells, possibly by enhancing nuclear retention of the molecular vector²⁷⁻³

To assess the increase in total histone H3 upon EEV overexpression, we transfected EEV-empty, EEV-H3.3 WT, and EEV-H3K9M into Neuro2a cells in vitro. Three days after transfection, we conducted nuclear protein extractions and quantified the total amount of histone H3 in each condition using Lamin B1 for normalization (Supplementary Fig. 2A, B). The cells transfected with EEV-H3.3 WT and EEV-H3K9M displayed a similar increase of total histone H3 in comparison to the cells transfected with EEV-empty, however, the relative increase was not statistically significant (Supplementary Fig. 2B). Thus, EEVs carrying mutant K-to-M histones produce variable increases in total histone H3 that must be experimentally accounted for with the EEV-H3.3 WT control. We performed IUE of EEV-H3.3 WT and EEV-H3K4M into embryonic day 14.5 (E14.5) mouse cerebral cortex, a developmental stage at which upper-layer (i.e. layers II-IV) excitatory neurons are born³¹. We collected the electroporated brains at postnatal day 8 (P8), a time point when upper-layer cortical neurons have completed their migration³¹. Our analysis focused on the depletion of H3K4 monomethylation (H3K4me1) and H3K4 trimethylation (H3K4me3). Using immunostaining, we quantified the levels of H3K4me1 and H3K4me3 in electroporated neurons, which also expressed nuclear GFP. Our analysis shows that H3K4M overexpression resulted in a robust and simultaneous depletion of H3K4me1 and H3K4me3 in comparison with the overexpression of the WT histone H3.3 (Fig. [2](#page-3-0)A, B). Most H3K4M-electroporated neurons expressed RBFOX3 (also known as NeuN) —a marker of mature neurons at P8 (Supplementary Fig. 3A). The electroporated neurons also expressed SATB2, a marker of callosal projections neurons in the cortex (Supplementary Fig. 3A)³². These results suggest that depletion of H3K4me1 and H3K4me3 does not lead to a general silencing of actively transcribed genes, as H3K4M-expressing cortical neurons survived and retained some molecular identity markers. Moreover, we combined the IUE of histone H3K4M with the supernova system^{[33](#page-11-12)}, which enabled the sparse labeling of electroporated neurons and the simultaneous depletion of H3K4me1 in comparison with the WT histone H3.3-electroporated controls (Supplementary Fig. 3B). This implementation will facilitate future studies directed at testing the role of histone methylations in the development of dendrites, axons, and synaptic contacts in cortical neurons.

We sought to determine whether the EEV-H3K9M enabled the simultaneous depletion of the repressive marks H3K9me2 and H3K9me3 in cortical neurons. We performed IUE of EEV-H3K9M at E14.5, which resulted in strong expression of the mutant histone in all electroporated neurons at P8 (Fig. [3](#page-4-0)A). We observed a strong depletion of H3K9me2 and H3K9me3 in most GFP⁺ neurons electroporated with H3K9M in comparison to neurons electroporated with WT histone H3.3 at P7-P8 (Fig. [3B](#page-4-0), C). In contrast, H3K9M expression did not have an overt impact on H3K9me1 —a histone mark associated with transcriptionally active genes (Supplementary Fig. 4A). Our findings indicate that expression of H3K9M leads to simultaneous depletion of the repressive marks H3K9me2 and H3K9me3 in vivo. This effect seems specific, as we did not find an apparent decrease of H3K27me3 in H3K9M-electroporated neurons at P8 (Supplementary Fig. 4B).

To test whether the expression of mutant histones facilitates the simultaneous depletion of H3K9me3 and H3K27me3 in cortical neurons, we performed IUE of EEV-H3K9M and EEV-H3K27M at E14.5 followed by the analysis of histone marks at P15. We observed a strong and simultaneous depletion of H3K9me3 and H3K27me3 in electroporated neurons in comparison to the non-electroporated cells (Fig. [4](#page-5-0)). In this experimental setting, H3K9me2 was depleted in some electroporated neurons whereas others retained the histone mark (Supplementary Fig. 5), likely as a consequence that the concentration of the two injected plasmids (EEV-H3K9M and EEV-H3K27M) was around half the concentration of the individually injected EEV-H3K9M (see the [Methods](#page-8-0) section). Therefore, the robust depletion of H3K9me2 and H3K9me3 described above (Fig. [3B](#page-4-0), C) likely depends on the amount of H3K9M that is expressed in developing neurons. Likewise, the expression of H3K27M produced a decrease of H3K27me2 in a subset of electroporated neurons (Supplementary Fig. 5). Together, our results suggest that this experimental approach is suitable for elucidating the functional interplay of H3K9 and H3K27 methylation in transcriptional repression and cell differentiation.

To explore the depletion dynamics of repressive histone marks, we evaluated H3K9me3 and H3K27me3 six days after IUE of H3K9M and H3K27M, respectively. We observed a substantial depletion of both histone marks in cortical neurons of neonatal pups (Supplementary Fig. 6A, B). However, H3K9me3 depletion at P0 was not as strong as the observed depletion at P8 (Supplementary Fig. 6B and Fig. [3C](#page-4-0)). Therefore, our results indicate that histone K-to-M mutants promote a rapid and progressive depletion of histone marks in the electroporated neurons.

EEVs do not integrate into the host genome and display variable copy numbers in transfected cells. Hence, we sought to compare the efficiency of histone methylation depletion by EEV-H3K9M with a previously reported doxycycline-inducible transgenic mouse line overexpressing a single copy of H3K9M[22.](#page-11-3) We also used a transgenic mouse line overexpressing a single copy of H3.3 WT as a control^{[22](#page-11-3)}. Daily administration of doxycycline to pregnant dams at E9.5 resulted in strong H3K9M induction in the E15.5 cortex (Supplementary Fig. 7A).

Surprisingly, we did not observe an apparent depletion of H3K9me2 or H3K9me3 in P0 cortical neurons after 10 days of doxycycline administration (Supplementary Fig. 7B). Unfortunately, we could not evaluate later time points, as the H3K9M transgenic animals did not survive past P0, possibly as a result of transgene activation in the whole animal. Hence, despite the caveat of producing variable increases of total histone H3, EEVs provide a stronger depletion of H3K9 methylation than a single-copy transgenic system.

To control the timing of mutant histone expression in cortical neurons, we generated a conditional system consisting of two vectors based on Cre-LoxP recombination. The first vector encodes a tamoxifen-inducible Cre that is flanked by the estrogen receptor ligand-binding domain (ERT2) on the N- and C-terminal ends (Fig. [5](#page-6-0)A). The inducible Cre is produced in a bicistronic transcript with tdTomato to label electroporated neurons independently of tamoxifen administration (Fig. [5](#page-6-0)A, B). The second vector contains a FLEX (Flip-Excision) switch that is irreversibly flipped upon Cre-mediated recombination of the LoxP/Lox2272 flanking sites to initiate expression of the WT or mutant histone H3 and GFP (Fig. [5](#page-6-0)A, B). To test for potential leakage of Cre activity, we initially injected both vectors at E14.5 and collected samples at P15 in the absence of tamoxifen administration. We found that the electroporated cortical neurons were labeled by tdTomato but no detectable levels of GFP were observed at the time of analysis (Supplementary Fig. 8), confirming that the inducible Cre that is flanked by ER^{T2} on the N- and C-terminal ends has no leakage³⁴. Next, we performed IUE at E14.5 of the Cre-inducible system using a FLEX vector coding for H3K27M, followed by tamoxifen administration in electroporated pups from P15 to P18. We observed the induction of GFP and H3K27M in all electroporated neurons at P18 (Fig. [5](#page-6-0)C). This result indicates that the inducible system enables the temporal control of gene induction in the cerebral cortex.

Fig. 3. Depletion of Histone H3K9 methylation in cortical neurons. E14.5 cortices were electroporated *in utero* with EEVs carrying GFP and histone H3.3 WT or H3K9M. GFP⁺ cortical neurons were analyzed at P7-P8. (**A**) High levels of H3K9M expression were confirmed in all electroporated neurons. (**B**, **C**) H3K9M produced a strong depletion of H3K9me2 and H3K9me3 in comparison to the H3.3 WT electroporated controls. Arrows indicate some examples. Data represent mean \pm SD; statistical analysis is unpaired Student's t-test $(****p<0.001).$

To test whether mutant histones promote the depletion of endogenous histone marks in the postnatal cortex, we performed IUE of WT histone H3.3, H3K27M, or H3K9M at E14.5, followed by tamoxifen administration in electroporated pups at P15-P18, and the analysis of histone marks at P70. We observed that the WT histone H3.3 did not impact H3K9me3 or H3K27me3 (Fig. [6](#page-7-0)A, B). In contrast, H3K9M and H3K27M induced the depletion of H3K9me3 and H3K27me3, respectively (Fig. [6](#page-7-0)A, B). Using this experimental design, we also observed

Fig. 4. Simultaneous depletion of Histone H3K9 and H3K27 methylation in cortical neurons. E14.5 cortices were electroporated *in utero* with EEVs carrying GFP, H3K9M, and H3K27M. GFP⁺ cortical neurons were analyzed at P15. A significant decrease of H3K9me3 and H3K27me3 was observed in electroporated cortical neurons (arrows) in comparison to nonelectroporated GFP[−] cells. Data represent mean ± SD; statistical analysis is unpaired Student's t-test (*****p*<0.001).

depletion of H3K9me3 and H3K27me3 in electroporated neurons as late as P100 (Supplementary Fig. 9A, B), indicating that inhibition of histone methylation is sustained in postmitotic cells for at least 2.5 months after tamoxifen administration. Our results show that the tamoxifen-inducible vector system enables the depletion of specific histone H3 methylations in fully differentiated cortical neurons in the early postnatal and adult brains.

Discussion

Elucidating the role of genome-wide histone H3 methylations in transcriptional regulation and cell differentiation remains a major challenge in mammals^{[4](#page-10-3),[8](#page-10-7)}. One significant hurdle is the presence of multiple copies of histone H3-coding genes in mammalian genomes. In mice for example, histone H3 has three isoforms (H3.1, H3.2, H3.3) encoded by 28 alleles³⁵. Notably, a recent study using CRISPR-mediated gene editing in cultured mESCs simultaneously mutated the sequence encoding lysine 27 in all histone H3 alleles³⁶. However, implementing this type of approach in a cell-type-specific manner in vivo remains a daunting technical challenge in mice. Furthermore, multiple histone H3 methyltransferases normally play redundant roles in the methylation of specific lysine residues^{[10](#page-10-9)}. Therefore, conditional mutations of individual methyltransferases do not usually result in a complete loss of histone H3 methylation^{[12,](#page-10-11)[37](#page-11-16)-39}. To overcome these limitations, we have optimized the overexpression and temporal control of histone H3 K-to-M mutants to inhibit the endogenous methylation of histone H3 in early postnatal and adult cortical neurons. We demonstrate that this relatively simple approach enables the robust depletion of at least two levels of methylation at individual or multiple lysine residues of histone H3 in vivo.

Canonical histones H3.1 and H3.2 are induced in the S-phase of the cell cycle and incorporated into nucleosomes during DNA replication⁴⁰. In contrast, histone H3.3 is replication-independent and primarily enriched at enhancers and promoters, suggesting a pivotal role of H3.3 in dynamic gene regulation 40 . The EEVs described in this study are based on histone H3.3, as this isoform naturally accumulates in newborn cortical neurons and controls their identity and connectivity[41.](#page-11-19) In contrast, overexpression of canonical H3.1 and H3.2 in cortical neurons could lead to altered H3 distribution in the genome, as these isoforms do not accumulate in postmitotic cells. For instance, H3.1K27M and H3.2K27M effectively silence H3K27me3 but show differential genomic enrichment in comparison to H3.3K27M[42](#page-11-20)[,43](#page-11-21). Furthermore, in some contexts, canonical K-to-M histones might not produce depletion of histone methylation⁴⁴. Our results suggest that the turnover of mitotically-deposited histone H3.1 and H3.2 is necessary for histone methylation depletion in postmitotic cells. The impact of distinct mutant histone H3 isoforms on methylation is an interesting topic that remains largely unexplored.

Previous studies have shown that histone H3 K-to-M mutants can inhibit methylation on a particular lysine residue with different strengths. H3K27M and H3K36M are strong inhibitors of the di- and trimethylated states of lysine 27 and 36, respectively[16,](#page-10-14)[22](#page-11-3), whereas H3K4M and H3K9M are weaker at inhibiting multiple methylation

Fig. 5. A conditional vector system for the temporal control of histone H3 expression. (**A**) The schematic shows a vector encoding a tamoxifen-inducible Cre and tdTomato and another vector with a FLEX cassette carrying H3K27M and GFP. (**B**) Experimental strategy to activate H3K27M in electroporated neurons of the postnatal cortex. (**C**) E14.5 cortices were electroporated with the two vectors shown in (**A**) and 4-hydroxytamoxifen was administered from P15 to P18. The electroporated cortical neurons displayed expression of TdTomato, GFP, and H3K27M at P18 (arrows).

states^{[22,](#page-11-3)[45](#page-11-23)}. In this regard, previous work showed that H3K4M overexpression in mouse adipocytes strongly silences H3K4me1 but has a mild effect on H3K4me3^{[45](#page-11-23)}. Although H3K4M expression was driven under a strong CAG promoter⁴⁵, the transgene integration into the host chromatin environment might reduce H3K4M levels and H3K4me3 depletion in adipocytes. In another study, H3K9M overexpression in a transgenic mouse line inhibited H3K9me3 but had little impact on H3K9me2 in adult hematopoietic cells, possibly as a consequence of H3K9M integration into the host genome as a single copy²². Unexpectedly, using the same H3K9M transgenic line, we did not observe an apparent depletion of H3K9me2 and H3K9me3 in cortical neurons. This result suggests that a single copy of H3K9M is not sufficient for robust inhibition of H3K9 methyltransferases in cortical neurons after 10 days of transgene induction. Here, we show that sustained high expression of H3K4M or H3K9M leads to a strong depletion of H3K4me1/3 or H3K9me2/3, respectively, in cortical neurons.

In our experimental setting, the initially electroporated cells in the E14.5 cerebral cortex primarily consist of proliferating NSCs and progenitors residing at the ventricular zone 24 . Standard molecular vectors are diluted more rapidly than EEVs during mitosis, resulting in decreased gene expression in proliferating cells and their differentiated progeny²⁷. EEVs display nuclear retention and self-replicate as extrachromosomal elements in human cells, thereby maintaining high gene expression levels upon multiple rounds of cell division^{25,46}. EEVs do not self-replicate in mouse cells but display high nuclear retention during mitosis^{[27–](#page-11-8)30}. Nuclear retention is mediated by the binding of EBNA1 protein to the direct repeat element of ori P^{47} —a mechanism that promotes the attachment between the plasmid and the nuclear matrix chromosomal scaffold in mitotic cells⁴⁸. Consistent with this notion, our results indicate that EEVs maintain high expression of mutant histones during proliferation and neuronal differentiation, resulting in robust depletion of two levels of histone H3 methylation.

We observed that a high concentration of EEV-H3K9M robustly inhibited H3K9me2 and H3K9me3, whereas a medium concentration of EEV-H3K9M strongly depleted H3K9me3 but had a partial impact on depleting H3K9me2. Distinct canonical histone methyltransferases are responsible for generating different H3K9 methylation states —EHMT1 (GLP) and EHMT2 (G9A) produce H3K9me2, while SETDB1, SETDB2, SUV39H1, and SUV39H2 generate H3K9me3[8](#page-10-7),[49.](#page-11-27) Previous evidence indicates that H3K9M inhibits EHMT2 and SUV39H1 in vitro¹⁶. However, our evidence suggests that H3K9M is less effective in vivo at inhibiting EHMT1/2 than at repressing SETDB1/2 and SUV39H1/2, as a higher concentration of H3K9M seems necessary to suppress EHMT1/2 activity. Unexpectedly, we did not observe depletion of H3K9me1 —a mark also generated by EHMT1/2^{8,49}. One possibility is that noncanonical H3K9 methyltransferases that are not sensitive to H3K9Mmediated inhibition might be compensating for the partial loss of EHMT1/2 activity in cortical cells. In this regard, it is interesting that the genes encoding for the noncanonical H3K9 methyltransferases PRDM16 and PRDM8 are highly expressed in NSCs and neurons of the embryonic cortex, respectively^{50–53}. Further studies

Fig. 6. Inducible depletion of histone H3K9 or H3K27 methylation in cortical neurons. E14.5 cortices were electroporated *in utero* with vectors carrying the inducible Cre and FLEX cassette, followed by tamoxifen administration from P15 to P18 to activate histone H3 genes. Histone H3 methylation was quantified in GFP⁺ cortical neurons at P70. H3K9M produced a significant decrease of H3K9me3 in comparison to histone H3.3 WT (**A**, arrows), whereas H3K27M expression resulted in depletion of H3K27me3 (**B**, arrows). Data represent mean±SD; statistical analysis is unpaired Student's t-test (*****p*<0.001).

are necessary to determine the full range of canonical and noncanonical histone methyltransferases that are repressed by mutant histones and their differential sensitivities to inhibition.

An outstanding open question in the field of epigenetics is how the coordinated activities of H3K9me3 and H3K27me3 regulate developmental gene expression and cell fate^{[9](#page-10-8)}. H3K9me3 and H3K27me3 are enriched within domains of constitutive and facultative heterochromatin^{[54](#page-11-30)}. Although H3K9me3- and H3K27me3decorated heterochromatin display only a partial overlap, the loss of H3K9me3 leads to the expansion of H3K27me3 and vice versa^{54[–58](#page-11-31)}. These observations suggest that H3K9me3 and H3K27me3 may cooperate in silencing transcription. However, the simultaneous depletion of H3K9me3 and H3K27me3 using conventional mouse genetics entails the generation of a line carrying at least six conditional loss-of-function mutations in the genes coding for the canonical H3K9me3 methyltransferases (*Setdb1*, *Setdb2*, *Suv39h1*, and *Suv39h2*) and H3K27me3 methyltransferases (*Ezh1* and *Ezh2*) —an unpractical approach. To overcome this limitation, we have leveraged the use of histone H3K9M and H3K27M mutants to concomitantly block the activity of H3K9 and H3K27 methyltransferases. Our results show a substantial and simultaneous depletion of H3K9me3 and H3K27me3 in cortical neurons. Future experiments with the vectors described in this study may be directed at testing the functional interplay of H3K9me3 and H3K27me3 in heterochromatin formation and the silencing of lineage-inappropriate genes in the developing cerebral cortex.

We report the generation of a conditional Cre-FLEX system to control the timing of depletion of specific histone H3 methylations. In comparison to the EEVs described here, the FLEX vectors offer the advantage of activating the mutant histones specifically in post-natal cortical neurons. Our results indicate that the decrease of H3K27me3 and H3K9me3 using the FLEX system is significant, albeit not as robust as the depletion observed with the EEVs vectors. This difference suggests that histone H3 mutants are more effective in decreasing histone

methylation during the early stages of neuronal differentiation than in mature neurons. This observation might reflect the fact that neuronal differentiation is accompanied by global changes in chromatin modifications[59](#page-11-32). Supporting this idea, recent findings indicate that accumulation of the histone H3.3 isoform in differentiating cortical neurons is important to establish their identity and axonal connectivity^{[41](#page-11-19)}. Therefore, the incorporation of histone H3.3 into nucleosomes during cortical neurogenesis could favor the generation of methylationdepleted histones in the presence of K-to-M mutants. In contrast, a consolidated chromatin landscape in mature neurons, together with a relatively slow histone H3 turnover⁶⁰, could reduce the generation rate of methylationdepleted histones. We propose that the combination of the EEVs and FLEX vectors described here will facilitate the distinction between the role of histone methylation in developmental lineage specification and mature cell functions.

Several studies have shown that overexpression of histone H3.3 K-to-M mutants dysregulates a similar subset of genes as the knockdowns of histone H3 methyltransferases targeting the same lysine residues $45,61$ $45,61$. Furthermore, histone H3.3 K-to-M mutants phenocopy mutations on genes encoding histone methyltransferases in invertebrates and mammalian cells^{[19](#page-11-1)[,45](#page-11-23)}. Thus, overexpression of K-to-M mutants produces functional changes that mirror the absence of histone methyltransferase activity.

Loss-of-function mutations in histone H3 methyltransferases and genome-wide changes in histone H3 methylation are associated with multiple neurodevelopmental disorders, brain tumors, aging, and neurodegeneration^{62–64}. The experimental use of histone H3 K-to-M mutants in invertebrate and vertebrate model organisms might contribute to our understanding of the role of histone H3 methylation in various human diseases. In this regard, the protein sequences of mouse and human histone H3.3 A are identical, suggesting that the vectors presented in this study should also inhibit histone methylation in human cells. Notably, EEVs selfreplicate in human cells, offering the possibility of long-term expression without genomic integration⁴⁶. This approach was used to reprogram adult human fibroblasts into induced pluripotent stem cells⁶⁵. Implementation of the tools described herein in mouse and human cell lineages that are easily accessible by electroporation or transfection will expand the use of mutant histones in exploring the role of the epigenome in development and disease.

Limitations of this study

The use of histone K-to-M mutants to investigate the role of histone methylation presents several important caveats, as highlighted in a recent review¹⁵. The primary limitation is the incomplete understanding of how these mutants inhibit histone methylation. In particular, it is not well understood how distinct histone methyltransferases are differentially inhibited by K-to-M mutants and the relative contribution of *cis* and *trans* effects on methylation depletion. Moreover, the vector system developed in this study introduces additional caveats that should be carefully considered during experimental design and result interpretation. The most important limitation is that EEVs drive relatively high and variable levels of histone H3 expression. While pleiotropic effects due to histone H3 overexpression have not been reporte[d15](#page-10-13), they cannot be entirely ruled out. To validate the experimental results with histone K-to-M mutants, a thorough comparison with genetic or pharmacological approaches targeting specific histone methyltransferases will be necessary.

Methods

All methods were performed in accordance with the Indiana University guidelines and regulations.

Experimental model

All the animal procedures conducted in this study complied with the protocol approved by the Institutional Animal Care and Use Committee (IACUC) of Indiana University. All mice used in this study for IUE were ICR (CD-1) outbred from Envigo. The transgenic mouse lines Col1a1-tetOP-H3.3 WT (The Jackson Laboratory No. 034364) and Col1a1-tetOP-H3.3K9M (The Jackson Laboratory No. 034366) were used for constitutive induction of histone H3.3 WT and H3K9M in vivo. Transgene expression in these lines is controlled by a tetracycline operator (tetO) that recognizes a doxycycline-inducible transactivator driven by a constitutively active Rosa26 promoter[22.](#page-11-3) Transgenic mice on a BL/6C57 background were crossed with CD-1 mice to promote embryo survival upon doxycycline administration to the pregnant dams. These crosses resulted in heterozygous embryos carrying a single copy of either H3.3 WT or H3K9M. To induce transgene expression, timed-pregnant dams were given 2.0 mg/ml doxycycline and 5% sucrose in drinking water from E9.5 to P0. The doxycycline solution was replaced every 7 days. Embryonic (E) day 15.5 and postnatal (P) day 0–70 mice were used in this study. The sex of the mouse embryos and pups was not determined. Mouse housing, husbandry, medical treatment, and euthanasia procedures followed the standards set by the Bloomington Institutional Animal Care and Use Committee (BIACUC). Euthanasia by CO_2 inhalation was confirmed by cervical dislocation. The authors complied with the ARRIVE guidelines.

*In utero***electroporation and tamoxifen administration**

Timed pregnant mice were anesthetized by isoflurane inhalation (3–5% for induction, 1–3% for maintenance). The anesthetized dams received a subcutaneous dose of buprenorphine (0.05–0.1 mg/kg) and were placed on top of a warming pad. The abdominal hair was removed using an electric clipper and the shaved abdomen was cleaned three times by alternating Iodine and alcohol wipes. An abdominal midline incision was made and the uterine horns were exposed on top of a sterile gauze pad. During the entire procedure, the open peritoneal cavity and the exposed uterine horns were kept moist with PBS 1X at 37°C. All electroporated plasmids were purified with an endotoxin-free maxi kit (Invitrogen) and dissolved in sterile PBS 1X containing 0.025% Fast Green (SIGMA). Approximately 1 µl of plasmid solution was manually injected into the forebrain ventricle of each embryo using heat-pulled/beveled glass micropipettes (Drummond). Once the whole litter was injected, 5 pulses of 30–40 V (50 ms duration and 950 ms intervals) were applied with 7 mm platinum electrodes connected to an ECM 830 square wave electroporator (BTX). The uterine horns were re-introduced into the peritoneal cavity and the incision was closed with an absorbable suture on a curved needle using a continuous locking stitch. The skin was then closed with sterile stainless steel wound clips. Ketoprofen (5 mg/kg) was subcutaneously administered to the anesthetized mouse to reduce pain. Mice were allowed to recover in a chamber set at 37° C until they ambulated stably about the chamber. A second dose of ketoprofen was administered 24 h post-surgery and the animals were monitored every day during the next seven days. The EEV encoding WT and mutant histone H3.3 were individually injected at 2–3 µg/µl. The Supernova plasmids pK031 (pTRE-Cre) and pK029 (pCAGloxP-stop-loxP-RFP-IRES-tTA-WPRE)[33](#page-11-12) were injected at 1.0 and 0.5 µg/µl, respectively, in combination with 2.0 µg/µl of the EEV encoding H3K4M or WT H3.3. The EEVs carrying H3K9M and H3K27M were co-injected at 1.5 µg/µl each. For the inducible system, the FLEX vectors carrying WT H3.3, H3K9M, or H3K27M were injected at $2 \mu g/\mu$ in combination with $1 \mu g/\mu$ of the plasmid encoding the tamoxifen-inducible Cre. Tamoxifen (SIGMA, T5648) was dissolved in sterile corn oil (SIGMA, C8267) at 20 mg/ml and aliquots were frozen at -20o C to prevent variability between batches. For induction of Cre-mediated recombination of the FLEX cassettes, tamoxifen was administered subcutaneously at 8 mg/40 gm of body weight in mouse pups every day from P15 to P18, as previously described 66 .

Cloning and site-directed mutagenesis

The mouse *H3f3a* sequence (encoding the histone H3.3 A isoform) upstream an IRES and nuclear GFP sequences were cloned into the EcoRI and NotI sites of EEV600A-1 (System Biosciences) to generate the EEV expressing the WT histone H3.3 A (supplementary Fig. 1). A Kozak consensus sequence (GCCACCATGG) in *H3f3a* was included in this vector to enhance the translation efficiency of histone H3.3 A. Custom primers were designed to mutate lysine 4, 9, or 27 into methionine on histone H3.3 A using the QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies #200521) following the manufacturer's instructions. All mutations were sequence-confirmed using custom primers.

To generate the vectors carrying the inducible histone H3.3, we cloned an IRES-GFP sequence into the SpeI site of pJ241-FLEX (Addgene #18925). To drive expression of the FLEX cassette under the EF1a promoter, the FLEX [IRES-GFP] sequence was introduced into the EcoRV-KpnI sites of pAAV-EF1a-FLEX-GTB (Addgene #26197) using infusion cloning (Takara Bio). This step swapped the FLEX cassette of pAAV-EF1a-FLEX-GTB for the FLEX [IRES-GFP] cassette. Finally, the WT and mutants histone H3.3 A were cloned into the EcoRI site of the FLEX [IRES-GFP] sequence to produce a plasmid in which the EF1a promoter controls expression of a FLEX [histone H3.3 A-IRES-GFP] cassette that produces functional gene products upon Cre-mediated recombination (Fig. [5](#page-6-0)A). To generate a vector encoding a tamoxifen-inducible Cre, we cloned CreER^{[[T2](#page-10-1)} (Cre recombinase fused to a mutant ligand-binding domain of the estrogen receptor) and IRES into the BamHI site of pAAV-EF1a-tdTomato-WPRE-pGHpA (Addgene #67527). To prevent leakage of Cre activity³⁴, we ligated a Kozak-ER^{[T[2](#page-10-1)} sequence upstream of the Cre to produce a vector encoding ER^{[T2}CreER^{[T2}-IRES-tdTomato downstream of the EF1a promoter. All vectors were sequence-confirmed.

Western blot

Neuro2a cells were transfected with Lipofectamine 3000 using 2 µg of EEV-empty, EEV-H3.3 WT, or EEV-H3K9M, and harvested after 72 h for nuclear protein extraction. Per 3×10^6 cells, 1 ml of cold nuclear isolation buffer (50 mM Tris-HCl pH 8, 15 mM NaCl, 60 mM KCl, 5 mM MgCl2, 1 mM CaCl2, 250 mM sucrose, 0.6% IGEPAL) supplemented with complete Halt protease inhibitor cocktail (Thermo Fisher) was gently added and incubated for 5 min on ice. Nuclei were centrifuged at 960 x g for 5 min and the pellet was washed twice in nuclear isolation buffer and lysed in RIPA buffer (50 mM Tris-HCL pH 8, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100 and 1 mM EDTA) supplemented with Halt protease inhibitor cocktail and 0.01 U/µl Benzonase (Millipore). Lysed Neuro2a cells were sonicated using an S220 Focused-ultrasonicate (Covaris) with 200 cycles/burst for 4 min. To remove cell debris, the lysates were centrifuged for 10 min at maximum speed. The supernatant was boiled together with Laemmli sample buffer (Bio-Rad) and loaded into 4–20% mini-Protean TGX precast protein gels (Bio-Rad). Protein was transferred to PVDF membranes and blocked in either 5% Bovine Serum Albumin in Tris-buffered saline and Tween 20 for 30 min at 4^o C or AdvanBlock-Flour (Advansta) for 1 h at room temperature. The following antibodies were used: anti-histone H3 (Cell Signaling Technologies, 4499T, 1:1000 dilution); anti-H3K9me3 (Active Motif, 39062, 1:1,000); anti-H3K9M (Invitrogen, MA5-33389, 1:1,000); anti-Lamin-B1 (Cell Signaling Technologies, 13435, 1:1,000); anti-GFP (Abcam, ab183734, 1:1000); secondary anti-rabbit IgG (LICORbio, 926-32211, 1:5000 dilution). Gels were imaged with the Odyssey CLx Imager (LICORbio). Western blot quantification was performed using ImageJ (National Institutes of Health, USA). Gel images were converted to 16-bit files and the rectangular selection tool was used to define the band area of histone H3 and Lamin B1. Profile plots were generated using the Gel analyzer tool to calculate the area under each peak, representing the relative band intensity. The relative band intensities of histone H3 were normalized against Lamin B1 to determine the relative increase of total H3 upon transfection of EEV-H3.3 WT and EEV-H3K9M.

Immunostaining

Early post-natal (P0-P15) and adult (P70) mice were anesthetized with an intraperitoneal injection of Xylazine (20 mg/Kg) - Ketamine (120–150 mg/Kg) and their brains were crosslinked by transcardially perfusing cold PBS pH 7.4 followed by 4% ethanol-free paraformaldehyde (PFA) diluted in PBS. The perfused brains were dissected and incubated overnight in 4% PFA with rocking at 4° C. The brains were washed three times in PBS and sectioned (75–100 μm thickness) in a VT1000 Vibratome (Leica Biosystems). Tissue sections were incubated in antigen retrieval solution (10 mM sodium citrate, 0.05% Tween 20, pH 6.0) for 1 hr at 70° C, colded down at room temperature (RT), and washed 3 times with PBS. Tissue sections were incubated for 1 hr at RT in blocking buffer (10% goat serum, 0.1% Triton X-100, 0.01% sodium azide diluted in PBS) before adding primary antibodies diluted in blocking buffer. Sections in primary antibody solution were incubated overnight at 4o C, washed three times with PBS, and incubated for 2 hr at RT with Alexa Fluor-conjugated secondary antibodies diluted in blocking buffer. Sections were washed again and the nuclei were stained with DAPI (4',6-diamidino-2-phenylindole) before mounting with Fluoromount-G (Southern Biotech). Primary antibodies against histone H3 methylation on lysine 4, 9, and 27 were selected based on The Histone Antibody Specificity Database ([http://](http://www.histoneantibodies.com/) www.histoneantibodies.com/ 67 . We used the following primary antibodies and dilutions: anti-H3K4me3 (Abcam, Ab8580, 1:6000), anti-H3K4me1 (Cell Signaling Technology, 5326T, 1:1000), anti-H3K9me3 (Active Motif, 39062, 1;1000), anti-H3K9me2 (Abcam, Ab1220, 1:1000), anti-H3K9me1 (Abcam, Ab8896, 1:1000), anti-H3K27me3 (Cell Signaling Technology, 9733 S, 1:1000), anti-H3K27me2 (Active Motif, 7408001, 1:1000), anti-H3K9M (Invitrogen, MA5-33389 1:1000), anti-H3K27M (Cell Signaling Technology, 74829 S, 1:2000), anti-GFP (Aves Labs Inc, GFP-1020, 1:4000), anti-RFP (MBL, PM005, 1:500), anti-NeuN (Millipore, MAB377, 1:300), anti-SATB2 (Santa Cruz, Sc-81376, 1:200). To detect primary antibodies, we used anti-rabbit and anti-mouse secondary antibodies conjugated to Alexa Fluor 488, 546, or 647 (Invitrogen, 1:500).

Imaging and quantifications

For each experimental condition, brains were collected from two CD-1 mouse litters. A minimum of 3 immunostained sections from two brains were used for imaging with a Leica SP8 confocal microscope and processed with the Las X Life Science microscope software (Leica Microsystems). Imaging settings were identical between the experimental and control groups. The pixel intensity of histone methylation was manually measured in 30–70 electroporated (GFP+) or non-electroporated (GFP−) cells for each condition using Image J/Fiji (National Institute of Health, USA). Briefly, single-plane images were converted to 16-bit files, and the threshold values of the GFP channel were adjusted to manually create regions of interest (ROIs) surrounding multiple GFP⁺ cells on an image. ROIs were then overlaid with the DAPI channel to ensure the selected cells did not overlap with other cells. For GFP− cells, ROIs were created in the DAPI channel. ROIs were then overlapped with the histone mark channel set at the default signal threshold and the pixel intensity for the histone methylation signal was measured within multiple ROIs. To reduce bias, ROIs were exclusively defined on the GFP or DAPI channels and without examining the histone methylation channel. To normalize for differences in signal intensity, we used the formula X New=X – Xmin / Xmax – Xmin, in which X represents the pixel intensity of the histone methylation staining in a cell. Accordingly, Xmin and Xmax were defined as the minimum and maximum pixel intensities of the histone methylation in electroporated cells for both control and experimental groups. Significance was determined using a two-tailed unpaired Student's t-test with the Prism Software (GraphPad) and reported as **p*<0.05, ***p*<0.01, ****p*<0.001, *****p*<0.0001.

Data availability

All data and molecular vectors presented in this paper will be made available upon request to the corresponding author.

Received: 19 January 2024; Accepted: 24 September 2024 Published online: 18 October 2024

References

- 1. Greer, E. L. & Shi, Y. Histone methylation: A dynamic mark in health, disease and inheritance. *Nat. Rev. Genet.* **13**, 343–357 (2012). 2. Jenuwein, T. & Allis, C. D. Translating the histone code. *Science* **293**(80), 1074–1080 (2001).
- 3. Farrelly, L. A. & Maze, I. An emerging perspective on 'histone code' mediated regulation of neural plasticity and disease. *Curr.*
- *Opin. Neurobiol.* **59**, 157–163 (2019). 4. Morgan, M. A. J. & Shilatifard, A. Reevaluating the roles of histone-modifying enzymes and their associated chromatin
- modifications in transcriptional regulation. *Nat. Genet.* **52**, 1271–1281 (2020). 5. Shen, E., Shulha, H., Weng, Z. & Akbarian, S. Regulation of histone H3K4 methylation in brain development and disease. *Philos.*
- *Trans. R. Soc. B Biol. Sci.* **369** (2014). 6. Sze, C. C. & Shilatifard, A. MLL3/MLL4/COMPASS family on epigenetic regulation of enhancer function and cancer. *Cold Spring Harb. Perspect. Med.* **6**, 1–15 (2016).
- 7. Henikoff, S. & Shilatifard, A. Histone modification: cause or cog?. *Trends Genet.* **27**, 389–396 (2011).
- 8. Padeken, J., Methot, S. P. & Gasser, S. M. Establishment of H3K9-methylated heterochromatin and its functions in tissue differentiation and maintenance. *Nat. Rev. Mol. Cell Biol.* **23**, 623–640 (2022).
- 9. Becker, J. S., Nicetto, D. & Zaret, K. S. H3K9me3-dependent heterochromatin: Barrier to cell fate changes. *Trends Genet.* **32**, 29–41 (2016).
- 10. Husmann, D. & Gozani, O. Histone lysine methyltransferases in biology and disease. *Nat. Struct. Mol. Biol.* **26**, 880–889 (2019).
- 11. Nicetto, D. *et al.* H3K9me3-heterochromatin loss at protein-coding genes enables developmental lineage specification. *Science* **363**(80), 294–297 (2019).
- 12. Dorighi, K. M. et al. Mll3 and Mll4 facilitate enhancer RNA synthesis and transcription from promoters independently of H3K4 monomethylation. *Mol. Cell* **66**, 568-576.e4 (2017).
- 13. Sze, C. C. et al. Histone H3K4 methylation-dependent and -independent functions of set1A/COMPASS in embryonic stem cell self-renewal and differentiation. *Genes Dev.* **31**, 1732–1737 (2017).
- 14. Park, I. Y. et al. Dual chromatin and cytoskeletal remodeling by SETD2. *Cell* **166**, 950–962 (2016).
- 15. Serdyukova, K. et al. Leveraging dominant-negative histone H3 K-to-M mutations to study chromatin during differentiation and development. *Development* **150**, 1–14 (2023).
- 16. Lewis, P. W. *et al.* Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. *Science* **340**(80), 857–861 (2013).
- 17. Wang, J. *et al.* Epigenomic landscape and 3D genome structure in pediatric high-grade glioma. *Sci. Adv.* **7** (2021).
- 18. Delaney, K., Strobino, M., Wenda, J. M., Pankowski, A. & Steiner, F. A. H3.3K27M-induced chromatin changes drive ectopic replication through misregulation of the JNK pathway in C. elegans. *Nat. Commun.* **10**, 1–15 (2019).
- 19. Herz, H. M. *et al.* Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling. *Science* **345**(80), 1065– 1070 (2014).
- 20. Nativio, R. et al. An integrated multi-omics approach identifies epigenetic alterations associated with Alzheimer's disease. *Nat. Genet.* **52**, 1024–1035 (2020).
- 21. Chaouch, A. *et al.* Histone H3.3 K27M and K36M mutations de-repress transposable elements through perturbation of antagonistic chromatin marks. *Mol. Cell* **81**, 4876–4890 (2021).
- 22. Brumbaugh, J. et al. Inducible histone K-to-M mutations are dynamic tools to probe the physiological role of site-specific histone methylation in vitro and in vivo. *Nat. Cell Biol.* **21**, 1449–1461 (2019).
- 23. Funato, K., Major, T., Lewis, P. W., Allis, C. D. & Tabar, V. Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation. *Science* **346**(80), 1529–1533 (2014).
- 24. Langevin, L. M. et al. Validating in utero electroporation for the rapid analysis of gene regulatory elements in the murine telencephalon. *Dev. Dyn.* **236**, 1273–1286 (2007).
- 25. Lufino, M. M. P., Edser, P. A. H. & Wade-Martins, R. Advances in high-capacity extrachromosomal vector technology: Episomal maintenance, vector delivery, and transgene expression. *Mol. Ther.* **16**, 1525–1538 (2008).
- 26. Henikoff, S. & Smith, M. M. Histone variants and epigenetics. *Cold Spring Harb. Perspect. Biol.* **7** (2015).
- 27. Tsukamoto, H. et al. Enhanced expression of recombinant dystrophin following intramuscular injection of Epstein-Barr virus (EBV)-based mini-chromosome vectors in mdx mice. *Gene Ther.* **6**, 1331–1335 (1999).
- Huertas, D., Howe, S., McGuigan, A. & Huxley, C. Expression of the human CFTR gene from episomal oriP-EBNA1-YACs in mouse cells. *Hum. Mol. Genet.* **9**, 617–629 (2000).
- 29. Stoll, S. M. et al. Epstein-Barr virus/human vector provides high-level, long-term expression of α1-antitrypsin in mice. *Mol. Ther.* **4**, 122–129 (2001).
- 30. Black, J. & Vos, J. M. Establishment of an oriP/EBNA1-based episomal vector transcribing human genomic β-globin in cultured murine fibroblasts. *Gene Ther.* **9**, 1447–1454 (2002).
- 31. Kwan, K. Y., Sestan, N. & Anton, E. S. Transcriptional co-regulation of neuronal migration and laminar identity in the neocortex. *Development* **139**, 1535–1546 (2012).
- 32. Alcamo, E. A. et al. Satb2 regulates callosal projection neuron identity in the developing cerebral cortex. *Neuron* **57**, 364–377 (2008)
- 33. Luo, W. et al. Supernova: A versatile vector system for single-cell labeling and gene function studies in vivo. *Sci. Rep.* **6**, 1–22 (2016).
- 34. Matsuda, T. & Cepko, C. L. Controlled expression of transgenes introduced by in vivo electroporation. *Proc. Natl. Acad. Sci. USA* **104**, 1027–1032 (2007).
- 35. Wang, Z. F. et al. Characterization of the mouse histone gene cluster on chromosome 13: 45 histone genes in three patches spread over 1 Mb. *Genome Res.* **6**, 688–701 (1996).
- 36. Sankar, A. et al. Histone editing elucidates the functional roles of H3K27 methylation and acetylation in mammals. *Nat. Genet.* **54**, 754–760 (2022).
- 37. Tan, S.-L.L. et al. Essential roles of the histone methyltransferase ESET in the epigenetic control of neural progenitor cells during development. *Dev.* **139**, 3806–3816 (2012).
- 38. Balan, S. et al. A loss-of-function variant in SUV39H2 identified in autism-spectrum disorder causes altered H3K9 trimethylation and dysregulation of protocadherin β-cluster genes in the developing brain. *Mol. Psychiatry* **12**, 7550–7559 (2021).
- 39. Denissov, S. et al. Mll2 is required for H3K4 trimethylation on bivalent promoters in embryonic stem cells, whereas Mll1 is redundant. *Development* **141**, 526–537 (2014).
- 40. Martire, S. & Banaszynski, L. A. The roles of histone variants in fine-tuning chromatin organization and function. *Nat. Rev. Mol. Cell Biol.* **21**, 522–541 (2020).
- 41. Funk, O. H., Qalieh, Y., Doyle, D. Z., Lam, M. M. & Kwan, K. Y. Postmitotic accumulation of histone variant H3.3 in new cortical neurons establishes neuronal chromatin, transcriptome, and identity. *Proc. Natl. Acad. Sci. USA* **119**, 1–12 (2022).
- 42. Sarthy, J. F. *et al.* Histone deposition pathways determine the chromatin landscapes of h3.1 and h3.3 k27m oncohistones. *Elife* **9**, 1–18 (2020).
- 43. Furth, N. et al. H3–K27M-mutant nucleosomes interact with MLL1 to shape the glioma epigenetic landscape. *Cell Rep.* **39**, 110836 (2022)
- 44. Aoshima, K., Inoue, E., Sawa, H. & Okada, Y. Paternal H3K4 methylation is required for minor zygotic gene activation and early mouse embryonic development. *EMBO Rep.* **16**, 803–812 (2015).
- 45. Jang, Y. *et al.* H3.3K4M destabilizes enhancer H3K4 methyltransferases MLL3/MLL4 and impairs adipose tissue development. *Nucleic Acids Res.* **47**, 607–620 (2019).
- 46. Nanbo, A., Sugden, A. & Sugden, B. The coupling of synthesis and partitioning of EBV's plasmid replicon is revealed in live cells. *EMBO J.* **26**, 4252–4262 (2007).
- 47. Yates, J. L., Camiolo, S. M. & Bashaw, J. M. The Minimal Replicator of Epstein-Barr Virus oriP. *J. Virol.* **74**, 4512–4522 (2000).
- 48. Jankelevich, S., Kolman, J. L., Bodnar, J. W. & Miller, G. A nuclear matrix attachment region organizes the Epstein-Barr viral plasmid in Raji cells into a single DNA domain. *EMBO J.* **11**, 1165–1176 (1992).
- 49. Montavon, T. et al. Complete loss of H3K9 methylation dissolves mouse heterochromatin organization. *Nat. Commun.* **12**, 1–12 (2021)
- 50. Pinheiro, I. et al. Prdm3 and Prdm16 are H3K9me1 methyltransferases required for mammalian heterochromatin integrity. *Cell* **150**, 948–960 (2012).
- 51. Baizabal, J. M. et al. The Epigenetic State of PRDM16-Regulated Enhancers in Radial Glia Controls Cortical Neuron Position. *Neuron* **98**, 945–962 (2018).
- 52. Eom, G. H. et al. Histone methyltransferase PRDM8 regulates mouse testis steroidogenesis. *Biochem. Biophys. Res. Commun.* **388**, 131–136 (2009).
- 53. Ross, S. et al. Bhlhb5 and Prdm8 form a repressor complex involved in neuronal circuit assembly. *Neuron* **73**, 292–303 (2012).
- 54. Becker, J. S. et al. Genomic and proteomic resolution of heterochromatin and its restriction of alternate fate genes. *Mol. Cell* **68**, 1023–1037 (2017).
- 55. Jamieson, K. et al. Loss of HP1 causes depletion of H3K27me3 from facultative heterochromatin and gain of H3K27me2 at constitutive heterochromatin. *Genome Res.* **26**, 97–107 (2016).
- 56. Peters, A. H. F. M. et al. Partitioning and plasticity of repressive histone methylation states in mammalian chromatin. *Mol. Cell* **12**, 1577–1589 (2003).
- 57. Harutyunyan, A. S. et al. H3K27M in gliomas causes a one-step decrease in H3K27 methylation and reduced spreading within the constraints of H3K36 methylation. *Cell Rep.* **33**, 108390 (2020).
- 58. Ho, J. W. K. et al. Comparative analysis of metazoan chromatin organization. *Nature* **512**, 449–452 (2014).
- 59. Albert, M. et al. Epigenome profiling and editing of neocortical progenitor cells during development. *EMBO J.* **36**, 2642–2658 (2017)
- 60. Maze, I. et al. Critical role of histone turnover in neuronal transcription and plasticity. *Neuron* **87**, 77–94 (2015).
- 61. Rajagopalan, K. N. *et al.* Depletion of H3K36me2 recapitulates epigenomic and phenotypic changes induced by the H3.3K36M oncohistone mutation. *Proc. Natl. Acad. Sci. USA* **118** (2021).
- 62. Reichard, J. & Zimmer-Bensch, G. The epigenome in neurodevelopmental disorders. *Front. Neurosci.* **15**, 1–23 (2021).
- 63. Lardenoije, R. et al. The epigenetics of aging and neurodegeneration. *Prog. Neurobiol.* **131**, 21–64 (2015).
- 64. Nacev, B. A. et al. The expanding landscape of 'oncohistone' mutations in human cancers. *Nature* **567**, 473–478 (2019).
- 65. Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, Slukvin II, T. J. Human Induced Pluripotent Stem Cells Free of Vector and Transgene Sequences. *Science* **324**(80), 797–802 (2009).
- 66. Kuo, C. T. et al. Postnatal deletion of Numb/Numblike reveals repair and remodeling capacity in the subventricular neurogenic niche. *Cell* **127**, 1253–1264 (2006).
- 67. Rothbart, S. B. et al. An interactive database for the assessment of histone antibody specificity. *Mol. Cell* **59**, 502–511 (2015).

Acknowledgements

We thank Justin Brumbaugh (University of Colorado, Boulder) for kindly donating the transgenic Col1a1-tetOP-H3.3 WT and Col1a1-tetOP-H3.3K9M mouse lines. We thank Heather O'Hagan and Jia Shen (both at Indiana University School of Medicine) for critically reading the manuscript. This work was supported by Indiana University startup funding to J-M.B.

Author contributions

S.W., S.X., and D.R.-M. performed all the experiments. S.W. quantified the results and prepared the figures. J-M.B. conceived the project, designed the experiments, and wrote the manuscript. All authors read and approved the final version of the manuscript.

Declarations

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at [https://doi.](https://doi.org/10.1038/s41598-024-74270-2) [org/10.1038/s41598-024-74270-2](https://doi.org/10.1038/s41598-024-74270-2).

Correspondence and requests for materials should be addressed to J.-M.B.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/](http://creativecommons.org/licenses/by-nc-nd/4.0/) [licenses/by-nc-nd/4.0/.](http://creativecommons.org/licenses/by-nc-nd/4.0/)

© The Author(s) 2024